Development of Biohybrid Multistage Nanovaccines for Melanoma : 11th European and Global Summit for Clinical Nanomedicine, Targeted Delivery and Precision Medicine

Flavia Fontana,Cristian Capasso,Mohammad‐Ali Shahbazi,Dongfei Liu,Manlio Fusciello,Sara Feola,Hongbo Zhang,Ermei Mäkilä,Jarno Salonen,Jouni Hirvonen,Vincenzo Cerullo,Hélder A. Santos

2018-01-01

Abstract:The treatment of melanoma has been revolutionized by the discovery of immune check-point inhibitors, antibodies that act at the level of the immunological synapsis or at the tumor level.[1] Active immunotherapy involves the reactivation of the patient’s immune system against the tumor.[2] Vaccines against tumor antigens are regarded as a mean to prime the immune system against the tumor cells.[3] Some of the challenges associated with the efficacy of the cancer vaccine are related to the poor adjuvancy of the antigenic peptides.[4] Thereby, newer adjuvants, in the form of particulate (micro or nano) systems, have been investigated.[5] In this context, thermally oxidized porous silicon (TOPSi) nanoparticles (NPs) induce the activation of antigen presenting cells, with a potential function as adjuvants.[6] In order to increase the efficacy of the adjuvant particles, we employed glass capillary microfluidics to encapsulate TOPSi NPs in a polymeric layer composed of acetalated dextran (AcDEX). AcDEX is a biocompatible polymer derived from the modification of dextran, with innate immunostimulative properties. TOPSi@AcDEX particles were able to induce the maturation of antigen presenting cells, as signified by the increased expression of co-stimulatory signals (CD80 and CD86; Figure 1) and by the secretion of pro-inflammatory cytokines (interferon gamma).[7] We added the antigenic component to the system by coating, through a process of membrane extrusion, the NPs with cellular membranes derived from cancer cells of interest, thereby formulating biohybrid nanovaccines.[7, 8] Figure 1. Percentage of CD86+ peripheral blood monocytes after incubation with nanosystems at two different concentrations (100 and 500 µg/mL). The results are presented as mean±s.d. (n=3) and have been analyzed with one-way ANOVA, followed by Bonferroni post-test. The level of significance was set at ***p